V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Apellis Pharmaceuticals Executive Compensation (FY24)

APLS · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Cedric Francois
Latest say-on-pay support
=
June 3, 2025
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Apellis Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 4, 2025
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Apellis Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
240 figures on this page: 235 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Cedric Francois: $10,373,049 → $10,957,451 (5.6% higher)
Say-on-pay support: 89.9% → 94.8% (4.9 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Apellis Pharmaceuticals' chief executive and what were they paid?
Cedric Francois was paid $10,957,451 in total compensation as President & Chief Executive Officer for fiscal 2024. Francois' total was 5.6% higher than the $10,373,049 reported for fiscal 2023.
What was Apellis Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 94.8% of votes cast for or against in favor at the meeting held June 3, 2025 for fiscal 2024.
Which companies are in Apellis Pharmaceuticals' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals, Alkermes plc, Amicus Therapeutics, Inc., Axsome Therapeutics, Inc. and Biocryst Pharmaceuticals, Inc, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Cedric Francois
President & Chief Executive Officer
◇◇◇◇——◇◇
Timothy Sullivan
Chief Financial Officer
◇◇◇◇——◇◇
Adam Townsend
Chief Commercial Officer
◇◇◇◇——◇◇
David Watson
General Counsel
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Cedric Francois
President & Chief Executive Officer
◇◇◇◇——◇◇
David Watson
General Counsel
◇◇◇◇——◇◇
Caroline Baumal
Chief Medical Officer
◇◇◇◇——◇◇
Timothy Sullivan
Chief Financial Officer
◇◇◇◇——◇◇
Adam Townsend
Chief Commercial Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Cedric Francois
President & Chief Executive Officer
◇◇◇◇——◇◇
Caroline Baumal
Chief Medical Officer
◇◇◇◇——◇◇
Adam Townsend
Chief Commercial Officer
◇◇◇◇——◇◇
Timothy Sullivan
Chief Financial Officer
◇◇◇◇——◇◇
David Watson
General Counsel
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Adam TownsendOPTION◇——◇—◇◇
Adam TownsendRSU◇——◇——◇
Caroline BaumalRSU◇——◇——◇
Caroline BaumalOPTION◇——◇—◇◇
Cedric FrancoisOPTION◇——◇—◇◇
Cedric FrancoisRSU◇——◇——◇
David WatsonOPTION◇——◇—◇◇
David WatsonRSU◇——◇——◇
Timothy SullivanOPTION◇——◇—◇◇
Timothy SullivanRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Caroline BaumalOption◇—◇1/2/33
RSU◇◇——
RSU◇◇——
Option◇—◇1/15/34
David WatsonRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/15/34
Option◇—◇1/11/33
Option◇—◇1/20/32
Option◇—◇1/27/31
Timothy SullivanRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/15/34
Option◇—◇1/11/33
Option◇—◇1/20/32
Option◇—◇1/27/31
Cedric FrancoisRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/15/34
Option◇—◇1/11/33
Option◇—◇1/20/32
Option◇—◇1/27/31
Adam TownsendRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/15/34
Option◇—◇1/11/33
Option◇—◇1/20/32
Option◇—◇1/27/31
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gerald Chan
◇◇◇———◇
Alec Machiels
◇◇◇———◇
Paul Fonteyne
◇◇◇———◇
Stephanie Monaghan O'Brien
◇◇◇———◇
A. Sinclair Dunlop
◇◇◇———◇
Keli Walbert, Cedric Francois and Craig Wheeler served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • ACADIA Pharmaceuticals ACAD
  • Alkermes plc ALKS
  • Amicus Therapeutics, Inc. FOLD
  • Axsome Therapeutics, Inc. AXSM
  • Biocryst Pharmaceuticals, Inc BCRX
  • Blueprint Medicines Corporation BPMC
  • Corcept Therapeutics Incorporated CORT
  • Insmed Incorporated INSM
  • Intra-Cellular Therapies, Inc. ITCI
  • Ionis Pharmaceuticals IONS
  • Madrigal Pharmaceuticals, Inc. MDGL
  • Neurocrine Biosciences NBIX
  • PTC Therapeutics PTCT
  • Ultragenyx Pharmaceuticals symbol not shown

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024June 3, 2025=◇◇◇
2023June 5, 2024=◇◇◇
2022June 1, 2023=◇◇◇
2021June 1, 2022=◇◇◇
2020June 1, 2021=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Cedric Francois (President & Chief Executive Officer), FY2024 total compensation $10,957,451 (base salary $793,193) [exec_comp, SEC accession 0000950170-25-056966, filed 2025-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Apellis Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Apellis Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Apellis Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Apellis Pharmaceuticals' disclosed peer group is defensible, who names Apellis Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
240 figures on this page: 235 cited to the filing that reported them, 5 calculated from figures it prints.
235 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001193125-25-134886
    The results of the stockholders’ non-binding advisory vote with respect to the compensation paid to the Company’s named executive officers were as follows: For Against Abstain Broker Non-Votes
  2. 0000950170-25-056966
    ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES · FURTHER INFORMATION REGARDING EXE CUTIVE COMPENSATION
  3. 0001193125-24-155179
    The results of the stockholders’ non-binding advisory vote with respect to the compensation paid to the Company’s named executive officers were as follows: For Against Abstain Broker Non-Votes
  4. 0000950170-24-049098
  5. 0001193125-23-158943
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  6. 0001193125-22-166256
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  7. 0001193125-21-178650
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Apellis Pharmaceuticals executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/APLS (accessed 2026).
Short form: data: Velarion

The Apellis Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Apellis Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Apellis Pharmaceuticals discloses

The companies named in APLS's own disclosed peer group.

ACADIA PharmaceuticalsAlkermes plcAmicus Therapeutics, Inc.Axsome Therapeutics, Inc.Biocryst Pharmaceuticals, IncBlueprint Medicines CorporationCorcept Therapeutics IncorporatedInsmed IncorporatedIntra-Cellular Therapies, Inc.Ionis PharmaceuticalsMadrigal Pharmaceuticals, Inc.Neurocrine BiosciencesPTC Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy